CN118359585A - 共晶体、其药物组合物以及涉及其的治疗方法 - Google Patents

共晶体、其药物组合物以及涉及其的治疗方法 Download PDF

Info

Publication number
CN118359585A
CN118359585A CN202410230044.7A CN202410230044A CN118359585A CN 118359585 A CN118359585 A CN 118359585A CN 202410230044 A CN202410230044 A CN 202410230044A CN 118359585 A CN118359585 A CN 118359585A
Authority
CN
China
Prior art keywords
compound
crystal
degrees
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410230044.7A
Other languages
English (en)
Chinese (zh)
Inventor
B·S·莱恩
C-H·顾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN118359585A publication Critical patent/CN118359585A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202410230044.7A 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法 Pending CN118359585A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
US62/580,501 2017-11-02
CN201880079771.0A CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880079771.0A Division CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法

Publications (1)

Publication Number Publication Date
CN118359585A true CN118359585A (zh) 2024-07-19

Family

ID=64572453

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410230044.7A Pending CN118359585A (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法
CN201880079771.0A Active CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880079771.0A Active CN111527076B (zh) 2017-11-02 2018-11-02 共晶体、其药物组合物以及涉及其的治疗方法

Country Status (25)

Country Link
US (3) US11345677B2 (enExample)
EP (1) EP3704101B1 (enExample)
JP (3) JP7335877B2 (enExample)
KR (1) KR102731624B1 (enExample)
CN (2) CN118359585A (enExample)
AU (3) AU2018360827B2 (enExample)
CA (1) CA3081535A1 (enExample)
DK (1) DK3704101T3 (enExample)
EA (1) EA202091112A1 (enExample)
ES (1) ES3075257T3 (enExample)
FI (1) FI3704101T3 (enExample)
HR (1) HRP20260783T1 (enExample)
IL (2) IL274123B2 (enExample)
LT (1) LT3704101T (enExample)
MA (1) MA50526B1 (enExample)
MX (2) MX2020004513A (enExample)
PH (1) PH12020550462A1 (enExample)
PT (1) PT3704101T (enExample)
RS (1) RS68236B1 (enExample)
SG (1) SG11202003612VA (enExample)
SI (1) SI3704101T1 (enExample)
SM (1) SMT202600262T1 (enExample)
TW (2) TWI796377B (enExample)
UA (1) UA127380C2 (enExample)
WO (1) WO2019090059A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
US20230346789A1 (en) * 2022-03-31 2023-11-02 Msd International Gmbh Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
CN121843929A (zh) * 2023-09-18 2026-04-10 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
US20250257050A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
MX2020004513A (es) 2020-09-17
BR112020008598A2 (pt) 2021-01-26
EP3704101B1 (en) 2026-05-06
CN111527076A (zh) 2020-08-11
IL274123B1 (en) 2023-09-01
IL305426B1 (en) 2024-06-01
MX2022014792A (es) 2023-01-16
JP7335877B2 (ja) 2023-08-30
HRP20260783T1 (hr) 2026-08-14
TWI796377B (zh) 2023-03-21
AU2026205552A1 (en) 2026-07-30
EP3704101A1 (en) 2020-09-09
KR102731624B1 (ko) 2024-11-19
US12679820B2 (en) 2026-07-14
CA3081535A1 (en) 2019-05-09
PT3704101T (pt) 2026-06-24
US11345677B2 (en) 2022-05-31
US20220363661A1 (en) 2022-11-17
CN111527076B (zh) 2024-03-12
FI3704101T3 (fi) 2026-06-12
UA127380C2 (uk) 2023-08-02
US11851417B2 (en) 2023-12-26
IL274123B2 (en) 2024-01-01
TW202337885A (zh) 2023-10-01
MA50526B1 (fr) 2026-06-30
AU2018360827A1 (en) 2020-05-14
JP2021501766A (ja) 2021-01-21
ES3075257T3 (en) 2026-07-29
IL305426A (en) 2023-10-01
SG11202003612VA (en) 2020-05-28
MA50526A (fr) 2020-09-09
JP2023093666A (ja) 2023-07-04
EA202091112A1 (ru) 2020-07-23
KR20240166601A (ko) 2024-11-26
US20240343705A1 (en) 2024-10-17
PH12020550462A1 (en) 2021-03-22
IL305426B2 (en) 2024-10-01
WO2019090059A1 (en) 2019-05-09
IL274123A (en) 2020-06-30
LT3704101T (lt) 2026-06-25
JP7780576B2 (ja) 2025-12-04
TW201930285A (zh) 2019-08-01
RS68236B1 (en) 2026-07-31
DK3704101T3 (da) 2026-06-15
AU2024203186A1 (en) 2024-05-30
JP2024113028A (ja) 2024-08-21
SI3704101T1 (sl) 2026-07-31
US20210198234A1 (en) 2021-07-01
JP7499377B2 (ja) 2024-06-13
AU2024203186B2 (en) 2026-04-16
SMT202600262T1 (it) 2026-07-16
AU2018360827B2 (en) 2024-02-22
TWI839131B (zh) 2024-04-11
KR20200095480A (ko) 2020-08-10

Similar Documents

Publication Publication Date Title
CN111527076B (zh) 共晶体、其药物组合物以及涉及其的治疗方法
EA048730B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA042081B1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
WO2021102221A1 (en) Deuterated analogs of an idh1 inhibitor
US20250034109A1 (en) Salts, cocrystals, pharmaceutical compositions thereof, and methods of treatment involving the same
CN121969614A (zh) Idh1抑制剂的共晶、其制备方法、其药物组合物及涉及其的治疗方法
BR112020008598B1 (pt) Cocristal, composição farmacêutica e usos de um cocristal ou de uma composição farmacêutica
WO2022173961A1 (en) Therapeutically active compounds and their methods of use
EA050372B1 (ru) Терапевтически активные соединения и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination